Gottlieb’s choice of Amy Abernethy as US FDA principal deputy could set her up to succeed him, should the need arise. CDER’s Cavazzoni will fill the post on temporary basis, elevating her profile within agency.
US FDA Commissioner Scott Gottlieb’s choice of Flatiron Health Inc. executive Amy Abernethy as his principal deputy commissioner to success a retiring Rachel Sherman offers one potential succession plan, should he decide to eventually leave the agency.
In Abernethy, Gottlieb brings to FDA an individual whose background neatly overlaps with much of the agency’s leadership over the...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
